Your browser doesn't support javascript.
loading
Real-world effectiveness of nivolumab and subsequent therapy in Japanese patients with metastatic renal cell carcinoma (POST-NIVO study): 36-month follow-up results of a clinical chart review.
Yonese, Junji; Hinata, Nobuyuki; Masui, Satoru; Nakai, Yasutomo; Shirotake, Suguru; Takeuchi, Ario; Inamoto, Teruo; Nozawa, Masahiro; Ueda, Kosuke; Etsunaga, Toru; Osawa, Takahiro; Uemura, Motohide; Kimura, Go; Numakura, Kazuyuki; Yamana, Kazutoshi; Miyake, Hideaki; Fukasawa, Satoshi; Morishima, Naoto; Ito, Hiroaki; Uemura, Hirotsugu.
Affiliation
  • Yonese J; Department of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan.
  • Hinata N; Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
  • Masui S; Division of Reparative and Regenerative Medicine, Nephro-Urologic Surgery and Andrology, Institute of Medical Life Science, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Nakai Y; Department of Urology, Osaka International Cancer Institute, Osaka, Japan.
  • Shirotake S; Department of Uro-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
  • Takeuchi A; Department of Urology, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
  • Inamoto T; Department of Urology, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
  • Nozawa M; Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan.
  • Ueda K; Department of Urology, Kurume University School of Medicine, Fukuoka, Japan.
  • Etsunaga T; Department of Urology, Isesaki Municipal Hospital, Isesaki, Gunma, Japan.
  • Osawa T; Department of Urology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.
  • Uemura M; Department of Urology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
  • Kimura G; Department of Urology, Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan.
  • Numakura K; Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
  • Yamana K; Department of Urology, Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Miyake H; Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.
  • Fukasawa S; Prostate Center and Division of Urology, Chiba Cancer Center, Chiba, Japan.
  • Morishima N; Oncology Medical Affairs, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
  • Ito H; Oncology Medical, Bristol-Myers Squibb K.K., Chiyoda-ku, Tokyo, Japan.
  • Uemura H; Department of Urology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan.
Int J Urol ; 30(9): 762-771, 2023 09.
Article in En | MEDLINE | ID: mdl-37248753
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Agents, Immunological / Kidney Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Int J Urol Journal subject: UROLOGIA Year: 2023 Type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antineoplastic Agents, Immunological / Kidney Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Int J Urol Journal subject: UROLOGIA Year: 2023 Type: Article Affiliation country: Japan